{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T23:10:47Z","timestamp":1794265847851,"version":"4.9.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54 CA242639"],"award-info":[{"award-number":["U54 CA242639"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA274950"],"award-info":[{"award-number":["R01 CA274950"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["CRP-23-1010710-06-COUN"],"award-info":[{"award-number":["CRP-23-1010710-06-COUN"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127447","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T12:12:52Z","timestamp":1751458372000},"page":"127447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201"],"prefix":"10.1016","volume":"61","author":[{"given":"Anna R.","family":"Giuliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Beltrame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa L.","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Lazcano-Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Santana-Bagur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betania","family":"Allen-Leigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra J.","family":"Portillo-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikrant V.","family":"Sahasrabuddhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret G.","family":"House","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Brofsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenice","family":"Galan de Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Carvalho da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Rathwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Isaacs-Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caique","family":"Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant B.","family":"Ellsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Wilkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127447_bb0005","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/jnci\/djad169","article-title":"Global epidemiologic patterns of oropharyngeal cancer incidence trends","volume":"115","author":"Zumsteg","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2025.127447_bb0010","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2025.127447_bb0015","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1470-2045(14)70471-1","article-title":"HPV DNA, E6\/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis","volume":"15","author":"Ndiaye","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0020","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00784-023-05425-0","article-title":"Global prevalence of human papillomavirus-related oral and oropharyngeal squamous cell carcinomas: a systematic review and meta-analysis","volume":"28","author":"Fons\u00eaca","year":"2023","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.vaccine.2025.127447_bb0025","doi-asserted-by":"crossref","first-page":"pky045","DOI":"10.1093\/jncics\/pky045","article-title":"Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58","volume":"2","author":"de Sanjos\u00e9","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.vaccine.2025.127447_bb0030","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2025.127447_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086023","article-title":"Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection","volume":"9","author":"D\u2019Souza","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127447_bb0040","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.oraloncology.2014.09.011","article-title":"Incidence and risk factors of HPV-related and HPV-unrelated head and neck squamous cell carcinoma in HIV-infected individuals","volume":"50","author":"Beachler","year":"2014","journal-title":"Oral Oncol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0045","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41571-024-00904-z","article-title":"Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination","volume":"21","author":"Malag\u00f3n","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.seminoncol.2015.09.011","article-title":"Cancer prevention in HIV-infected populations","volume":"43","author":"Goncalves","year":"2016","journal-title":"Semin Oncol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106321","article-title":"Current and future vaccine clinical research with the licensed 2-, 4-, and 9-valent VLP HPV vaccines: what\u2019s ongoing, what\u2019s needed?","volume":"144","author":"Kuter","year":"2021","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2025.127447_bb0060","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/14737140.2022.2088514","article-title":"Is 2045 the best we can do? Mitigating the HPV-related oropharyngeal cancer epidemic","volume":"22","author":"Schuman","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.vaccine.2025.127447_bb0065","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males","volume":"2019","author":"Bergman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2025.127447_bb0070","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/14760584.2023.2287135","article-title":"Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis","volume":"22","author":"Lin","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2025.127447_bb0075","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S1470-2045(15)70075-6","article-title":"Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging","volume":"16","author":"Lowy","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106592","article-title":"Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men","volume":"115","author":"Giuliano","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.vaccine.2025.127447_bb0085","series-title":"US-Latin American-Caribbean HIV\/HPV-Cancer Prevention Clinical TRials Network (ULACNet)","year":"2025"},{"key":"10.1016\/j.vaccine.2025.127447_bb0090","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1001\/jamaoto.2019.0119","article-title":"Human papillomavirus genotype detection in Oral gargle samples among men with newly diagnosed oropharyngeal squamous cell carcinoma","volume":"145","author":"Martin-Gomez","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.vaccine.2025.127447_bb0095","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1158\/1055-9965.EPI-08-0151","article-title":"The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States","volume":"17","author":"Giuliano","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2025.127447_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2020.100199","article-title":"Oral HPV prevalence assessment by linear Array vs. SPF(10) PCR-DEIA-LiPA(25) system in the HPV infection in men (HIM) study","volume":"9","author":"Bettampadi","year":"2020","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2025.127447_bb0105","series-title":"Biological Agents. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans","first-page":"100B","author":"IARC","year":"2012"},{"key":"10.1016\/j.vaccine.2025.127447_bb0110","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/CVI.00348-09","article-title":"Multiplexed serologic assay for nine anogenital human papillomavirus types","volume":"17","author":"Opalka","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0115","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1093\/cid\/ciy274","article-title":"A randomized, placebo-controlled trial of the quadrivalent human papillomavirus vaccine in human immunodeficiency virus-infected adults aged 27 years or older: AIDS Clinical Trials Group protocol A5298","volume":"67","author":"Wilkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127447_bb0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127447_bb0125","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.127447_bb0130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/CCO.0b013e32836242b4","article-title":"Oral human papillomavirus infection and head and neck cancers in HIV-infected individuals","volume":"25","author":"Beachler","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098955","article-title":"Six-month incidence and persistence of oral HPV infection in HIV-negative and HIV-infected men who have sex with men","volume":"9","author":"Mooij","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127447_bb0140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/aje\/kwu247","article-title":"Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults","volume":"181","author":"Beachler","year":"2015","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0145","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1158\/1055-9965.EPI-23-1272","article-title":"Oncogenic Oral human papillomavirus clearance patterns over 10 years","volume":"33","author":"D\u2019Souza","year":"2024","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2025.127447_bb0150","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1097\/QAD.0000000000001072","article-title":"Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy","volume":"30","author":"Shiboski","year":"2016","journal-title":"Aids"},{"key":"10.1016\/j.vaccine.2025.127447_bb0155","doi-asserted-by":"crossref","first-page":"866","DOI":"10.7326\/M17-2499","article-title":"Projected Cancer incidence rates and burden of incident Cancer cases in HIV-infected adults in the United States through 2030","volume":"168","author":"Shiels","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2025.127447_bb0160","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1002\/ijc.32713","article-title":"Oral human papillomavirus prevalence and type distribution by country (Brazil, Mexico and the United States) and age among HPV infection in men study participants","volume":"146","author":"Bettampadi","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2025.127447_bb0165","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1200\/JCO.2015.61.6995","article-title":"Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma","volume":"33","author":"Gillison","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0170","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.ejca.2015.09.005","article-title":"Human papillomavirus genotype and oropharynx cancer survival in the United States of America","volume":"51","author":"Goodman","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2025.127447_bb0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1042\/CS20210344","article-title":"Mechanisms of immune aging in HIV","volume":"136","author":"Chauvin","year":"2022","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.vaccine.2025.127447_bb0180","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.127447_bb0185","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/s41564-024-01824-5","article-title":"Multinational epidemiological analysis of oral human papillomavirus incidence in 3,137 men","volume":"9","author":"Dube Mandishora","year":"2024","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2025.127447_bb0190","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/ijc.34517","article-title":"Oral human papillomavirus (HPV) infection and HPV vaccination in an Australian cohort","volume":"153","author":"de Souza","year":"2023","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2025.127447_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127447_bb0200","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/OLQ.0000000000001405","article-title":"Human papillomavirus vaccine to end oropharyngeal Cancer. A systematic review and Meta-analysis","volume":"48","author":"Tsentemeidou","year":"2021","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2025.127447_bb0205","first-page":"69","article-title":"Risk factors associated with severe recurrent respiratory papillomatosis","volume":"34","author":"Khan","year":"2019","journal-title":"S Afr J Infect Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2025.127447_bb0210","first-page":"s2","article-title":"British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015","volume":"17","author":"Geretti","year":"2016","journal-title":"HIV Med"},{"key":"10.1016\/j.vaccine.2025.127447_bb0215","first-page":"645","article-title":"Human papillomavirus vaccines","volume":"50","author":"World Health Organization","year":"2022","journal-title":"WHO position paper Weekly Epidemiological"},{"key":"10.1016\/j.vaccine.2025.127447_bb0220","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1086\/656320","article-title":"Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men","volume":"202","author":"Wilkin","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2025.127447_bb0225","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.vaccine.2019.03.034","article-title":"Oral and systemic HPV antibody kinetics post-vaccination among HIV-positive and HIV-negative men","volume":"37","author":"Pinto","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127447_bb0230","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/21645515.2019.1656481","article-title":"A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus","volume":"16","author":"Mavundza","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.127447_bb0235","first-page":"11","article-title":"Efficacy and durability of immune response after receipt of HPV vaccines in people living with HIV","author":"Losada","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.127447_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101585","article-title":"Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: a systematic review and meta-analysis","volume":"52","author":"Staadegaard","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.vaccine.2025.127447_bb0245","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.vaccine.2019.01.069","article-title":"Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: a randomized, phase 3, placebo-controlled study","volume":"37","author":"Mikamo","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127447_bb0250","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1542\/peds.2014-3745","article-title":"Immunogenicity and safety of a 9-valent HPV vaccine","volume":"136","author":"Van Damme","year":"2015","journal-title":"Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25007443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25007443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T17:43:18Z","timestamp":1762278198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25007443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":50,"alternative-id":["S0264410X25007443"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127447","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial 201","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127447"}}